June 2019 - Volume 3 - Issue - Contributor Index

Author:
Vaccaro, E.
Author:
Vaclavu, L.
Author:
Vaddi, K.

FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS: PS1037

Ravandi, F.; Tallman, M.; Roboz, G.; More

HemaSphere. 3:468-469, June 2019.

Author:
Vadher, B.

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY: PF691

Todd, S.; Infirri, Sardo S.; Miah, H.; More

HemaSphere. 3:299-300, June 2019.

Author:
Vadikolia, C.

RECLASSIFICATION OF BIPHENOTYPIC ACUTE LEUKEMIA INTO MIXED-PHENOTYPE ACUTE LEUKEMIA ACCORDING TO WHO CRITERIA REFINES PATIENT CHARACTERIZATION AND PROGNOSIS; DISEASE MARKERS AND IMPACT ON OUTCOME: PF191

Douka, V.; Kotta, K.; Chatziioannidis, A.; More

HemaSphere. 3:47-48, June 2019.

Author:
Vaes, M.
Author:
VAGDATLI, E.
Author:
Vago, E.
Author:
Vago, L.

ELDERLY PATIENTS WITH DE NOVO OR SECONDARY AML HAVE COMPARABLE OUTCOMES AFTER INTENSIVE TREATMENTS INCLUDING HIGH DOSE (HD) CYTARABINE AND AUTOLOGOUS (AUTO) OR ALLOGENEIC (ALLO) TRANSPLANTATION (SCT): PS1061

Bernardi, M. S.; Carrabba, M. G.; Pavesi, F.; More

HemaSphere. 3:480, June 2019.

Author:
Vainchenker, W.
Author:
Vajia, P.

THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME: PF537

Lamprianidou, E.; Kordella, C.; Zoulia, E.; More

HemaSphere. 3:221-222, June 2019.

Author:
Vakrmanova, B.

MONOCYTIC SWITCH AND DISCREPANCY BETWEEN FLOW CYTOMETRIC AND MOLECULAR MINIMAL RESIDUAL DISEASE ARE FREQUENT IN DUX4 REARRANGED AND PAX5-P80R MUTATED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA: PF176

Novakova, M.; Vakrmanova, B.; Slamova, L.; More

HemaSphere. 3:40-41, June 2019.

Author:
Valcárcel, D.

BIOLOGICAL AND CLINICAL FACTORS THAT FAVOR THE USE OF A SPECIFIC TPO-RA IN ITP PATIENTS. RESULTS FROM A SPANISH MULTICENTER STUDY: PF339

Lozano, M. L.; Mingot, M. E.; Perera, M.; More

HemaSphere. 3:121-122, June 2019.

PREDICTORS OF THERAPY FREE RESPONSES IN ITP PATIENTS RECEIVING TPO-RA. RESULTS FROM A SPANISH MULTICENTER STUDY: PF690

Lozano, M. L.; Mingot, M. E.; Perera, M.; More

HemaSphere. 3:299, June 2019.

PREVALENCE AND RISK FACTORS FOR THROMBOSIS IN ADULT ITP PATIENTS TREATED WITH TPO-RA: PS1580

Lozano, M. L.; Mingot, M. E.; Perera, M.; More

HemaSphere. 3:728, June 2019.

COMPREHENSIVE ANALYSIS OF THE COMPLEXITY AND HETEROGENEITY OF THE LNCRNAS TRANSCRIPTOME IN MULTIPLE MYELOMA: PF583

Carrasco-Leon, A.; Ezponda, T.; Meydan, C.; More

HemaSphere. 3:243, June 2019.

Author:
Valchuk, M.
Author:
Valencia, J.
Author:
Valent, E.
Author:
Valent, P.

GENETICS AND MODELING OF HUMAN ACUTE ERYTHROID LEUKEMIA: S113

Fagnan, A.; Piqué Borràs, Riera M.; Ignacimouttou, C.; More

HemaSphere. 3:8-9, June 2019.

IMPACT OF 1ST LINE TREATMENT ON OVERALL SURVIVAL IN 1.633 PATIENTS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA - A MULTINATIONAL COLLABORATIVE EFFORT COORDINATED BY THE AGMT STUDY GROUP: S840

Pleyer, L.; Leisch, M.; Kouraklis, A.; More

HemaSphere. 3:374-375, June 2019.

MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL: PS1331

Geissler, K.; Jäger, E.; Barna, A.; More

HemaSphere. 3:607-608, June 2019.

SETD2 NON-GENOMIC LOSS OF FUNCTION IN ADVANCED SYSTEMIC MASTOCYTOSIS (SM): PATHOGENETIC AND THERAPEUTIC IMPLICATIONS: PS1437

Mancini, M.; Monaldi, C.; De Santis, S.; More

HemaSphere. 3:662-663, June 2019.

MARS: MUTATION-ADJUSTED RISK SCORE FOR ADVANCED SYSTEMIC MASTOCYTOSIS: S1611

Jawhar, M.; Schwaab, J.; Álvarez-Twose, I.; More

HemaSphere. 3:742-743, June 2019.

ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS): PF419

Montero, Casado L.F.; García-Ormeña, N.; Valentín, G.-G. J; More

HemaSphere. 3:162-163, June 2019.

Author:
Valeri, A.
Author:
Valeri, F.

ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP: PF695

Lucchini, E.; Palandri, F.; Volpetti, S.; More

HemaSphere. 3:302, June 2019.

Author:
Valerianova, M.

PHASE II STUDY OF ORAL RIGOSERTIB COMBINED WITH AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES (MDS): S839

Navada, S. C.; Garcia-Manero, G.; Atallah, E.; More

HemaSphere. 3:373-374, June 2019.

Author:
Valganon, M.
Author:
Valimberti, I.
Author:
Valjalo, R.
Author:
Valk, P.

HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA: PS1003

Bullinger, L.; Valk, P.; Versluis, J.; More

HemaSphere. 3:451, June 2019.

Author:
Valk, P. J.

COMPREHENSIVE DIAGNOSTICS OF ACUTE MYELOID LEUKEMIA BY WHOLE TRANSCRIPTOME RNA SEQUENCING: PF262

Griffioen, M.; Arindrarto, W.; Borràs, D. M.; More

HemaSphere. 3:83, June 2019.

Author:
Valkovic, T.

CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL-07FRAIL): PF182

Ribera, J. M.; García-Calduch, O.; Gil, C.; More

HemaSphere. 3:43, June 2019.

Author:
Vallance, G.
Author:
Vallansot, R.

CURRENT DOSE RECOMMENDATIONS FOR PONATINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS CAN DIMINISH ADVERSE EVENTS WHILE MAINTAINING EFFICACY: PS1186

Garcia-Gutierrez, V.; Hernandez-Boluda, J. C.; Moiraghi, B.; More

HemaSphere. 3:540-541, June 2019.

Author:
Valle, S.
Author:
Vallejo, A.
Author:
Vallejo, M.
Author:
Vallerini, D.

EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY: PS1274

Bettelli, F.; Giusti, D.; Morselli, M.; More

HemaSphere. 3:583, June 2019.

Author:
Vallone, A.

DECITABINE VERSUS INTENSIVE CHEMOTHERAPY IN ELDERLY UNTREATED ACUTE MYELOID LEUKEMIA: PS1031

De La Fuente, A.; Tormo, M.; Beneit, P.; More

HemaSphere. 3:465-466, June 2019.

Author:
Valls, J.

OLIGOMONOCYTIC CHRONIC MYELOMONOCYTIC LEUKEMIA (O-CMML) SHARES IMMUNOPHENOTYPIC AND MOLECULAR CHARACTERISTICS WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): PS994

Calvo, X.; Párraga, I.; Ferrer, A.; More

HemaSphere. 3:447, June 2019.

Author:
Valvano, M. R.

IBRUTINIB, SINGLE AGENT BTK INHIBITOR, FOR RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA: A REAL-WORLD EXPERIENCE FROM RETE EMATOLOGICA PUGLIESE (REP).: PB1901

Scalzulli, P. R.; Guarini, A.; Loseto, G.; More

HemaSphere. 3:866-867, June 2019.

Author:
Vályi-Nagy, I.
Author:
van Alphen, F.
Author:
van Baarle, F.
Author:
van Balen, P.
Author:
van Beers, E.

PROGNOSIS IN ELDERLY MULTIPLE MYELOMA PATIENTS IN THE HOVON-87/NMSG-18 STUDY BASED ON REVISED ISS AND SKY92-ISS: PS1374

Kuiper, R.; Broijl, A.; van Vliet, M. H.; More

HemaSphere. 3:628-629, June 2019.

Author:
Van Belle, S.
Author:
van Bergen, C.

COMPREHENSIVE DIAGNOSTICS OF ACUTE MYELOID LEUKEMIA BY WHOLE TRANSCRIPTOME RNA SEQUENCING: PF262

Griffioen, M.; Arindrarto, W.; Borràs, D. M.; More

HemaSphere. 3:83, June 2019.

Author:
van Bergen, M.
Author:
van Bladel, D.
Author:
Van Bogaert, C.
Author:
van Boxtel, R.
Author:
van Bruggen, J.

CHRONIC LYMPHOCYTIC LEUKEMIA CELLS IMPAIR MITOCHONDRIAL FITNESS IN T CELLS AND IMPEDE CAR T CELL EFFICACY: PS1134

Van Bruggen, J. A. C.; Martens, A. W. J.; Fraietta, J. A.; More

HemaSphere. 3:513-514, June 2019.

Author:
Van Damme, A.

TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT: PF204

Depreter, B.; Weening, K.; Vandepoele, K.; More

HemaSphere. 3:54, June 2019.

Author:
van de Donk, N.

POMALIDOMIDE PLUS LOW-DEXAMETHASONE TREATMENT FOR ≥ 1 YEAR IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: A SUBANALYSIS OF THE MM-013 PHASE 2 STUDY: PB2117

Weisel, K.; Dimopoulos, M.; Cook, M.; More

HemaSphere. 3:953, June 2019.

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS: S145

Moreau, P.; Attal, M.; Hulin, C.; More

HemaSphere. 3:24-25, June 2019.

IBERDOMIDE (CC-220) IS PHARMACODYNAMICALLY ACTIVE AND HAS DOSE-DEPENDENT IMMUNOSTIMULATORY ACTIVITY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IRRESPECTIVE OF PRIOR IMID DRUG TREATMENT: PF559

Amatangelo, M.; Gaudy, A.; Bjorklund, C.; More

HemaSphere. 3:231-232, June 2019.

STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY: PF598

Hulin, C.; Moreau, P.; Attal, M.; More

HemaSphere. 3:252, June 2019.

Show: